Abstract Number: 0006 • ACR Convergence 2024
NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Background/Purpose: Bruton’s tyrosine kinase (BTK) mediates signaling downstream of the B cell receptor (BCR), toll-like receptors (TLRs), and Fc receptors (FcRs). This makes BTK an…Abstract Number: 0808 • ACR Convergence 2024
Confirmation of Second Trimester Trophoblast Transport of Maternal Anti-SSA/Ro52 and 60kD Autoantibodies in Cardiac Neonatal Lupus: Implications for FcRn Blockade
Background/Purpose: The nearly invariant finding of anti-SSA/Ro52/60kD autoantibodies in pregnancies complicated by cardiac neonatal lupus (cardiac-NL), which manifests as fetal atrioventricular block and endocardial fibroelastosis…Abstract Number: 0840 • ACR Convergence 2024
The Platelet Adenosinergic Axis as a Novel Therapeutic Target for Thrombotic APS
Background/Purpose: How to most effectively inhibit antiphospholipid antibodies (aPL)-mediated platelet activation remains incompletely understood. CD73 is an ectoenzyme expressed on the platelet surface that generates…Abstract Number: 1795 • ACR Convergence 2024
Immune Complexes-Mediated Activation of Neutrophils in Systemic Lupus Erythematosus Is Dependent on RNA Recognition by TLR8
Background/Purpose: Neutrophil activation has been implicated to contribute to the systemic lupus erythematosus (SLE) pathogenesis. However, factors and mechanisms promoting neutrophil activation in SLE have…Abstract Number: 1864 • ACR Convergence 2024
S-4321, a Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
Background/Purpose: The dysregulation of immune checkpoint receptors on T cells and antigen presenting cells (APCs) drives autoimmunity while receptor agonism is expected to restore immune…Abstract Number: 1978.5 • ACR Convergence 2024
Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
Background/Purpose: Nipocalimab is a fully human, high affinity, aglycosylated, effectorless IgG1 monoclonal antibody designed to selectively block neonatal fragment crystallizable receptor (FcRn), thereby lowering IgG…Abstract Number: 1988 • ACR Convergence 2024
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Background/Purpose: Nipocalimab is a human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn) that selectively reduces IgG levels without impacting antigen presentation, T- and…Abstract Number: 2254 • ACR Convergence 2024
A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers
Background/Purpose: ZB004 is a bioengineered cytotoxic T-lymphocyte-associated antigen 4 ‑immunoglobulin (CTLA-4-Ig) fusion protein. Its mechanism of action is selective inhibition of T lymphocyte (T cell)…Abstract Number: 2527 • ACR Convergence 2024
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of specific autoantibodies (AAb) and lymphocytic infiltration of exocrine glandular tissues.…Abstract Number: 0051 • ACR Convergence 2023
CD14+CD64+ Classical Monocytes Are the Main Producers of IL-23 at the Enthesis
Background/Purpose: IL-23 is a key cytokine involved in diseases such as psoriasis, psoriatic arthritis and spondyloarthropathies (SpA) and inflammatory bowel disease.IL-23 is produced by activated…Abstract Number: 2144 • ACR Convergence 2023
Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study
Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that blocks the neonatal crystallizable fragment receptor (FcRn), thereby lowering IgG levels. RA…Abstract Number: 2232 • ACR Convergence 2023
Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23
Background/Purpose: Monoclonal antibodies (mAbs) targeting the interleukin (IL)-23p19 subunit are effective in treating psoriatic disease; however, their molecular attributes may translate to differences in clinical…Abstract Number: 1854 • ACR Convergence 2022
Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions
Background/Purpose: Nipocalimab, a fully human, effectorless IgG1 anti-neonatal Fc receptor (FcRn) monoclonal antibody, binds to FcRn with high affinity which prevents IgG recycling, leading to…Abstract Number: 2030 • ACR Convergence 2022
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…Abstract Number: 0044 • ACR Convergence 2021
Autoantibodies Against Malondialdehyde-modifications Promote Osteoclast Development by Reprogramming Cellular Metabolism
Background/Purpose: Malondialdehyde (MDA) is a highly reactive compound generated during lipid-peroxidation in conditions associated with oxidative stress. MDA can irreversibly modify proteins (e.g. lysine, arginine…
ACR Meeting Abstracts